43. Kikuchi Y, Hirata J, Yamamoto K, Ishi K, Kita T, Kudoh K, Tode T, Nagata I, Taniguchi K, Kuwano M. Altered expression of ?-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells. Jpn J Cancer Res 1997; 88: 213-7.

44. Hirata J, Kikuchi Y, Kita T, Imaizumi EE, Tode T, Ishii K, Kudoh K, Nagata I. Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum (II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-Buthionine-S,R-Sulphoximine. Int J Cancer 1993; 55: 521-7.

45.Sugimoto C, Matsukawa S, Fujieda S, Noda I, Tanaka N, Tsuzuki H, Saito H. Involvement of intracellular glutathione in induction of apoptosis by cisplatin in a human pharyngeal carcinoma cell line. Anticancer Res 1996; 16: 675-80.

46. Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ. Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Cancer Chemother Pharmacol 1997, 40 (1): 38-44.

47. Kurokawa H, Nishio K, Ishida T, Arioka H, Fukuoka K, Nomoto T, Fukumoto H, Yokote H, Saijo N. Effect of glutathione depletion on cisplatin resistance in cancer cells transfected with the ? -glutamylcysteine synthetase gene. Jpn J Cancer Res 1997; 88: 108-10.

48. Campling BG, Baer K, Baker HM, Lam YM. Cole SPC. Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer ctll lines? Br J Cancer 1993; 68: 327-35.

49. Kodera Y, Akiyama S, Isobe K, Kondo K, Ito K, Yamauchi M, Takagi H. Expression of ?-glutathione S-transferase gene (GSTP1) in gastric cancer: lack of correlation with resistance against cis-diamminedichloroplatinum (II). Eur J Cancer 1994; 30A: 2158-62.

50. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993; 68: 240-50.

51. Eichholtz-Wirth H, Reidel G, Hietel B. Radiation-induced transient cisplatin resistance in murine fibrosarcoma cells associated with elevated metallothionein content. Br J Cancer 1993; 67: 1001-6.

52. Lazo JS, Basu A. Metallothionein expression and transient resistance to electrophilic antineoplastic drugs. Semin Cancer Biol 1991; 2: 267-71.

53. Hishikawa Y, Abe SI, Kinugasa S, Yoshimura H, Monden N. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology 1997; 54: 342-7.

54. Vaisman A, Vachenko M, Said I, Chaney SG. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 1997; 27: 54-64.

55. Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtinger-Schepman AMJ, Shellard SA. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 1994; 30A: 832-7.

56. Johnson SW, Swiggard PA, Handel LM, Godwin AK, Ozols RF, Hamilton TC. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and resistant human ovarian cancer cells. Cancer Res 1994, 54: 5911-6.

57. Turchi JJ, Li M, Henkels KM. Cisplatin-DNA binding specificity of calf high mobility group I protein. Biochem 1996; 35: 2992-3000.

58.Ikeda S, Ozaki K. Action of mitochondrial endonuclease G on DNA damaged by L-ascorbic acid, peplomycin, and cis-diamminedichloroplatinum (II). Biochem Biophys Res Commun 1997, 235(2): 291-4.

59. Bissett D, McLaughlin K, Kelland LR, Brown R. Cisplatin-DNA damage recognition proteins in human tumor extracts. Br J Cancer 1993; 67:742-8.

60. McLaughlin K, Coren G, Masters J, Brown R. Binding activities of cis-platin-damage-recognition proteins in human tumor cell lines. Int J Cancer 1993; 53: 662-6.

61. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, Zee AG, Anthoney DA. HMLN1 expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 1997, 15(1): 45-52.

62. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N, Viano I, Colangelo D, Leone R, Apostoli P, Cassinelli G, Gambetta RA, Zunino F. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem Pharmacol 1998, 55(8): 1247-54.

63. Fishel R, Ewel A, Lescoe MC. Purified human MSH2 protein binds to DNA containing mismatched nucleotides. Cancer Res 1994; 54: 5539-42.

64. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994; 54: 5059-63.

65. Chu G. Cellular responces to Cisplatin. J Biol Chem 1994; 269: 787-90.

66. Sorenson CM, Eastman A. Influence of cis-Diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient hamster ovary cells. Cancer Res 1988; 48: 6703-7.

67. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998, 273 (36): 23419-25.

68. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res 1998, 58 (6): 1120-3.

69. Mestdach N, Pommery N, Saucier JM, Hecquet B, Founier C, Slomianny C, Teissier E, Henichart JP. Chemoresistance to doxorubicin and cisplatin